Evidence map›Paper›PMID 35265573›Full record

ArticleFrontiers in public health2022

The Impact of the COVID-19 Pandemic on Head and Neck Cancer Diagnosis in the Piedmont Region, Italy: Interrupted Time-Series Analysis.

Maja Popovic, Valentina Fiano, Giovenale Moirano, Luigi Chiusa, David I Conway, Paolo Garzino Demo, Marco Gilardetti, Giuseppe Carlo Iorio, Chiara Moccia, Oliviero Ostellino and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The COVID-19 pandemic has not changed stage at presentation nor treatment patterns of head and neck cancer: A retrospective cohort study.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Maja PopovicCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Valentina FianoCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Giovenale MoiranoCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Luigi ChiusaPathology Unit, Azienda Ospedaliero-Universitaria (A.O.U.) Città della Salute e della Scienza Hospital, Turin, Italy.
David I ConwaySchool of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, United Kingdom.
Paolo Garzino DemoMaxillofacial Unit, Azienda Ospedaliero-Universitaria (A.O.U.) Città della Salute e della Scienza Hospital, Turin, Italy.
Marco GilardettiSC Epidemiologia dei Tumori CRPT U, Azienda Ospedaliero-Universitaria (A.O.U.) Città della Salute e della Scienza di Torino, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica (CPO) Piemonte, Turin, Italy.
Giuseppe Carlo IorioDepartment of Oncology, University of Turin, Turin, Italy.
Chiara MocciaCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Oliviero OstellinoOncology Unit, Azienda Ospedaliero-Universitaria (A.O.U.) Città della Salute e della Scienza Hospital, Turin, Italy.
Giancarlo PecorariDivision of Otorhinolaryngology, Department of Surgical Sciences, University of Turin, Turin, Italy.
Guglielmo RamieriMaxillofacial Unit, Azienda Ospedaliero-Universitaria (A.O.U.) Città della Salute e della Scienza Hospital, Turin, Italy.
Umberto RicardiDepartment of Oncology, University of Turin, Turin, Italy.
Giuseppe RivaDivision of Otorhinolaryngology, Department of Surgical Sciences, University of Turin, Turin, Italy.
Shama ViraniGenomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Lorenzo RichiardiCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITCentre International de Recherche sur le Cancer · FRUniversity of Glasgow · GB

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: The COVID-19 pandemic has likely affected the most vulnerable groups of patients and those requiring time-critical access to healthcare services, such as patients with cancer. The aim of this study was to use time trend data to assess the impact of COVID-19 on timely diagnosis and treatment of head and neck cancer (HNC) in the Italian Piedmont region. Methods: This study was based on two different data sources. First, regional hospital discharge register data were used to identify incident HNC in patients ≥18 years old during the period from January 1, 2015, to December 31, 2020. Interrupted time-series analysis was used to model the long-time trends in monthly incident HNC before COVID-19 while accounting for holiday-related seasonal fluctuations in the HNC admissions. Second, in a population of incident HNC patients eligible for recruitment in an ongoing clinical cohort study (HEADSpAcE) that started before the COVID-19 pandemic, we compared the distribution of early-stage and late-stage diagnoses between the pre-COVID-19 and the COVID-19 period. Results: There were 4,811 incident HNC admissions in the 5-year period before the COVID-19 outbreak and 832 admissions in 2020, of which 689 occurred after the COVID-19 outbreak in Italy. An initial reduction of 28% in admissions during the first wave of the COVID-19 pandemic (RR 0.72, 95% CI 0.62-0.84) was largely addressed by the end of 2020 (RR 0.96, 95% CI 0.89-1.03) when considering the whole population, although there were some heterogeneities. The gap between observed and expected admissions was particularly evident and had not completely recovered by the end of the year in older (≥75 years) patients (RR: 0.88, 0.76-1.01), patients with a Romano-Charlson comorbidity index below 2 (RR 0.91, 95% CI: 0.84-1.00), and primary surgically treated patients (RR 0.88, 95% CI 0.80-0.97). In the subgroup of patients eligible for the ongoing active recruitment, we observed no evidence of a shift toward a more advanced stage at diagnosis in the periods following the first pandemic wave. Conclusions: The COVID-19 pandemic has affected differentially the management of certain groups of incident HNC patients, with more pronounced impact on older patients, those treated primarily surgically, and those with less comorbidities. The missed and delayed diagnoses may translate into worser oncological outcomes in these patients.

Indexed as

COVID-19Head and Neck NeoplasmsAdolescentAgedCohort StudiesHumansItalyPandemicsSARS-CoV-2cancercancer detectionCOVID-19head and neckhead and neck cancersinterrupted time-series analysis (ITSA)Italytime trend analyses

Identifiers

PMID35265573
PMCPMC8899030
OpenAlexW4213062919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.